I accepted very quickly that Charlie was disabled and I accepted the worst. I didn’t try to hang onto the hope that he was ...
Harbaji, W. and Abdulai, A. (2025) Factors Influencing Schoolchildren’s Obesity: A Qualitative Document Analysis of ...
Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...
SGLT2 inhibitors significantly improved glycaemic control and reduced the albumin-to-creatinine ratio without affecting body weight in patients with Prader-Willi syndrome and type 2 diabetes (T2D); ...
Treatment with intranasal carbetocin was not associated with a statistically significant improvement in hyperphagia compared with placebo. Topline results were announced from a phase 3 trial ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple ...
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients ...
Soleno Therapeutics is breathing easier with a report from Acadia Pharmaceuticals that its candidate to treat hyperphagia in patients with Prader-Willi Syndrome (PWS) has come up short in a phase 3 ...
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint Acadia Pharmaceuticals Inc. (Nasdaq ...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...
Hosted on MSN
Soleno Therapeutics Shares Surge After Competitor’s Prader-Willi Treatment Misses Endpoint
Soleno Therapeutics (NASDAQ:SLNO) saw its stock climb 14% following news that Acadia Pharmaceuticals’ (NASDAQ:ACAD) Phase 3 trial for a Prader-Willi syndrome therapy failed to meet its primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results